Clinical data | |
---|---|
Other names | SCH-727965 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.246.885 |
Chemical and physical data | |
Formula | C21H28N6O2 |
Molar mass | 396.495 g·mol−1 |
3D model (JSmol) | |
| |
|
Dinaciclib (SCH-727965) is an experimental drug that inhibits cyclin-dependent kinases (CDKs).[1] It is being evaluated in clinical trials for various cancer indications.[2]
Dinaciclib is being developed by Merck & Co. It was granted orphan drug status by the FDA in 2011.[3]
In primary cultured neurons, dinaciclib regulates neurogenesis, where it reduces expression of upper layer marker Satb2, and induces CTIP2, expressed in neurons of deeper layers.[11]